Reversal of tumorigenicity and the block to differentiation in erythroleukemia cells by GATA-1

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6363-6369

  Choe, Kevin S ^a   Radparvar, Farshid ^a   Matushansky, Igor ^a   Rekhtman, Natasha ^a   Han, Xing ^a   Skoultchi, Arthur I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROTEIN P21; RNA; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PU 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROLEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION REGULATION;

ANIMALS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; DOWN-REGULATION; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; GATA1 TRANSCRIPTION FACTOR; GENE THERAPY; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MICE; MICE, INBRED DBA; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS;

EID: 0141953999     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Friend, C., Scher, W., Holland, J. G., and Sato, T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA, 68: 378-382, 1971.
2. Gallagher, R. E. Arsenic: new life for an old potion. N. Engl. J. Med., 339: 1389-1391, 1998.
3. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93: 5705-5708, 1996.
4. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., and Richon, V. M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61: 8492-8497, 2001.
5. Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D., and Richon, V. M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res., 19: 4999-5005, 1999.
6. Fenrick, R., and Hiebert, S. W. Role of histone deacetylases in acute leukemia. J. Cell. Biochem. Suppl., 31: 194-202, 1998.
7. Hong, S. H., Yang, Z., and Privalsky, M. L. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with lts transcription factor partners, including the PML-retinoic acid receptor α oncoprotein found in human acute promyelocytic leukemia. Mol. Cell. Biol., 21: 7172-7182, 2001.
8. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998.
9. Marks, P. A., Sheffery, M., and Rifkind, R. A. Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res., 47: 659-666, 1987.
10. Moreau-Gachelin, F., Tavitian, A., and Tambourin, P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature (Lond.), 331: 277-280, 1988.
11. Paul, R., Schuetze, S., Kozak, S. L., and Kabat, D. A common site for immortalizing proviral integrations in Friend erythroleukemia: molecular cloning and characterization. J. Virol., 63: 4958-4961, 1989.
12. Goebl, M. K. The PU.1 transcription factor is the product of the putative oncogene Spi-1. Cell, 61: 1165-1166, 1990.
13. Scott, E. W., Simon, M. C., Anastasi, J., and Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science (Wash. DC), 265: 1573-1577, 1994.
14. McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., and Maki, R. A. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J., 15: 5647-5658, 1996.
15. Schuetze, S., Stenberg, P. E., and Kabat, D. The Ets-related transcription factor PU.1 immortalizes erythroblasts. Mol. Cell. Biol., 13: 5670-5678, 1993.
16. Moreau-Gachelin, F., Wendling, F., Molina, T., Denis, N., Titeux, M., Grimber, G., Briand, P., Vainchenker, W., and Tavitian, A. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol. Cell. Biol., 16: 2453-2463, 1996.
17. Schuetze, S., Paul, R., Gliniak, B. C., and Kabat, D. Role of the PU.1 transcription factor in controlling differentiation of Friend erythroleukemia cells. Mol. Cell. Biol., 12: 2967-2975, 1992.
18. Galson, D. L., Hensold, J. O., Bishop, T. R., Schalling, M., D'Andrea, A. D., Jones, C., Auron, P. E., and Housman, D. E. Mouse β-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to hematopoietic cells and the testis. Mol. Cell. Biol., 13: 2929-2941, 1993.
19. Delgado, M. D., Hallier, M., Meneceur, P., Tavitian, A., and Moreau-Gachelin, F. Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides. Oncogene, 9: 1723-1727, 1994.
20. Rao, G., Rekhtman, N., Cheng, G., Krasikov, T., and Skoultchi, A. I. Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene, 14: 123-131, 1997.
21. Rekhtman, N., Radparvar, F., Evans, T., and Skoultchi, A. I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev., 13: 1398-1411, 1999.
22. Tsang, A. P., Visvader, J. E., Turner, C. A., Fujiwara, Y., Yu, C., Weiss, M. J., Crossley, M., and Orkin, S. H. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell, 90: 109-119, 1997.
23. Matushansky, I., Radparvar, F., and Skoultchi, A. I. Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors. Blood, 96: 2755-2764, 2000.
24. Matushansky, I., Radparvar, F., and Skoultchi, A. I. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. USA, 97: 14317-14322, 2000.
25. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J. Y. D-Type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol., 14: 2066-2076, 1994.
26. Evans, T., and Felsenfeld, G. trans-Activation of a globin promoter in nonerythroid cells. Mol. Cell. Biol., 11: 843-853, 1991.
27. Mizushima, S., and Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res., 18: 5322, 1990.
28. Gusella, J. F., Weil, S. C., Tsiftsoglou, A. S., Volloch, V., Neumann, J. R., Keys, C., and Housman, D. E. Hemin does not cause commitment of murine erythroleukemia (MEL) cells to terminal differentiation. Blood, 56: 481-487, 1980.
29. Gresser, I., Moss, J., Woodrow, D., Le Bousse, C., Maury, C., Proietti, E., and Belardelli, F. Influence of the site of tumor growth on the capacity of a low tumorigenic line of Friend erythroleukemia cells to differentiate. Am. J. Pathol., 138: 1125-1133, 1991.
30. Kirsch, I. R., Bertness, V., Silver, J., and Hollis, G. F. Regulated expression of the c-myb and c-myc oncogenes during erythroid differentiation. J. Cell. Biochem., 32: 11-21, 1986.
31. Lachman, H. M., and Skoultchi, A. I. Expression of c-myc changes during differentiation of mouse erythroleukaemia cells. Nature (Lond.), 310: 592-594, 1984.
32. Clarke, M. F., Kukowska-Latallo, J. F., Westin, E., Smith, M., and Prochownik, E. V. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol. Cell. Biol., 8: 884-892, 1988.
33. Dmitrovsky, E., Kuehl, W. M., Hollis, G. F., Kirsch, I. R., Bender, T. P., and Segal, S. Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature (Lond.), 322: 748-750, 1986.
34. Prochownik, E. V., and Kukowska, J. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation. Nature (Lond.), 322: 848-850, 1986.
35. Yamada, T., Kondoh, N., Matsumoto, M., Yoshida, M., Maekawa, A., and Oikawa, T. Overexpression of PU.1 induces growth and differentiation inhibition and apoptotic cell death in murine erythroleukemia cells. Blood, 89: 1383-1393, 1997.
36. Matushansky, I., Radparvar, F., and Skoultchi, A. I. CDK6 blocks differentiation: Coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene, 22: 4143-4149, 2003.
37. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes & Development, 9: 935-944, 1995.
38. Hsieh, F. F., Barnett, L. A., Green, W. F., Freedman, K., Matushansky, I., Skoultchi, A. I., and Kelley, L. L. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Blood, 96: 2746-2754, 2000.
39. Levenson, R., and Housman, D. Developmental program of murine erythroleukemia cells. Effect of the inhibition of protein synthesis. J. Cell Biol., 82: 715-725, 1979.
40. Sieweke, M. H., and Graf, T. A transcription factor party during blood cell differentiation. Curr. Opin. Genet. Dev., 8: 545-551, 1998.
41. Zhang, P., Behre, G., Pan, J., Iwama, A., Wara-Aswapati, N., Radomska, H. S., Auron, P. E., Tenen, D. G., and Sun, Z. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl. Acad. Sci. USA, 96: 8705-8710, 1999.
42. Nerlov, C., Querfurth, E., Kulessa, H., and Graf, T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood, 95: 2543-2551, 2000.
43. Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K. A., Mueller, B. U., Narravula, S., Torbett, B. E., Orkin, S. H., and Tenen, D. G. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood, 96: 2641-2648, 2000.
44. Nerlov, C., and Graf, T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev., 12: 2403-2412, 1998.
45. Moreau-Gachelin, F., Ray, D., Mattei, M. G., Tambourin, P., and Tavitian, A. The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias. Oncogene, 4: 1449-1456, 1989.
46. Chen, H., Ray-Gallet, D., Zhang, P., Hetherington, C. J., Gonzalez, D. A., Zhang, D. E., Moreau-Gachelin, F., and Tenen, D. G. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene, 11: 1549-1560, 1995.
47. Tsai, S. F., Strauss, E., and Orkin, S. H. Functional analysis and in vivo footprinting implicate the erythroid transcription factor GATA-1 as a positive regulator of its own promoter. Genes Dev., 5: 919-931, 1991.
48. Shimamoto, T., Ohyashiki, K., Ohyashiki, J. H., Kawakubo, K., Fujimura, T., Iwama, H., Nakazawa, S., and Toyama, K. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood, 86: 3173-3180, 1995.
49. Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., and Tenen, D. G. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood, 100: 998-1007, 2002.
50. Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., and Behre, G. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood, 101: 270-277, 2003.
51. Friend, C., and Rossi, G. B. The phenomenon of differentiation in murine virus-induced leukemic cells. Proc. Can. Cancer Conf., 8: 171-182, 1969.